Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.46 |
| ▸ | CDK2 | P24941 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.41 |
| ▸ | FYN | P06241 | 2/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29582918 | 1.00 | HCAR3 (0.49) | HCAR3HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL17075516 | 0.98 | HCAR3 (0.48) | HCAR3HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL29944834 | 0.90 | HDAC3 (0.46) | HCAR3HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL2817349 | 0.90 | HDAC3 (0.46) | HCAR3HDAC3HDAC1HDAC2HDAC6 | |
| Lithium Ion SCHEMBL17075514 | 0.85 | HDAC3 (0.45) | HCAR3HDAC3HDAC1HDAC2HDAC6 | |
| Fumaric Acid SCHEMBL30856933 | 0.85 | HCAR3 (0.42) | HCAR3HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL2790974 | 0.84 | PCSK9 (0.56) | HDAC3HDAC1HDAC2HDAC6CCNE1 | |
| SCHEMBL25387892 | 0.78 | S1PR1 (0.48) | CCNE1CDK2 | |
| SCHEMBL30000505 | 0.78 | S1PR1 (0.48) | CCNE1CDK2 | |
| SCHEMBL15511812 | 0.76 | CCNE1 (0.72) | HCAR3CCNE1CDK2MAPK1MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230110165-A1 | Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof | PROXIMAGEN LLC (US) | 2023-04-13 | — | — | US | disclosed |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200347059-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN, LLC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10766897-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200262835-A1 | COMPOUNDS | PROXIMAGEN, LLC (US) | 2020-08-20 | — | — | US | disclosed |
| US-10590125-B2 | Compounds | PROXIMAGEN, LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-10428066-B2 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2019-10-01 | — | — | US | disclosed |
| EP-2970260-B1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180194763-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-9951068-B2 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors | PROXIMAGEN LIMITED (GB) | 2018-04-24 | — | — | US | disclosed |
| US-20170247378-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN, LLC | 2017-08-31 | — | — | US | disclosed |
| US-9676769-B2 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors | PROXIMAGEN LIMITED (GB) | 2017-06-13 | — | — | US | disclosed |
| US-20160326172-A1 | NEW COMPOUNDS | PROXIMAGEN, LLC | 2016-11-10 | — | — | US | disclosed |
| US-20160326172-A1 | NEW COMPOUNDS | PROXIMAGEN, LLC | 2016-11-10 | — | — | US | disclosed |
| US-9428498-B2 | Substituted imidazo[4,5-c]pyridine compounds and compositions thereof | PROXIMAGEN LIMITED (GB) | 2016-08-30 | — | — | US | disclosed |
| US-9428498-B2 | Substituted imidazo[4,5-c]pyridine compounds and compositions thereof | PROXIMAGEN LIMITED (GB) | 2016-08-30 | — | — | US | disclosed |
| US-20150258101-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| WO-2014140592-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275040-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140275040-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590125-B2 | Compounds | ALOX15B, ALOX12, ALOX15 | HCAR3 660/4885HDAC3 2894/4885HDAC1 1649/4885 |
| US-20160326172-A1 | NEW COMPOUNDS | SSB, ALOX15B, ALOX12 | HCAR3 511/4885HDAC3 3108/4885HDAC1 1874/4885 |
| US-10766897-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PNPO, SSB, XDH | HCAR3 1797/4885HDAC3 1948/4885HDAC1 699/4885 |
| US-10428066-B2 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors | PNPO, SSB, XDH | HCAR3 1797/4885HDAC3 1948/4885HDAC1 699/4885 |
| US-20140275040-A1 | NEW COMPOUNDS | SSB, ALOX15B, ALOX12 | HCAR3 511/4885HDAC3 3108/4885HDAC1 1874/4885 |
| US-20170247378-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PNPO, SSB, XDH | HCAR3 1797/4885HDAC3 1948/4885HDAC1 699/4885 |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PNPO, PPOX, SCO2 | HCAR3 2704/4885HDAC3 2167/4885HDAC1 1019/4885 |
| US-20230110165-A1 | Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof | PNPO, XDH, EPX | HCAR3 1754/4885HDAC3 629/4885HDAC1 481/4885 |
| US-20200347059-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PNPO, PPOX, SCO2 | HCAR3 2704/4885HDAC3 2167/4885HDAC1 1019/4885 |
| US-20200262835-A1 | COMPOUNDS | QSOX1, AOX1, EPX | HCAR3 1215/4885HDAC3 687/4885HDAC1 318/4885 |
| US-20180194763-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PNPO, SSB, XDH | HCAR3 1797/4885HDAC3 1948/4885HDAC1 699/4885 |
| US-20150258101-A1 | NEW COMPOUNDS | AOX1, QSOX1, MAOB | HCAR3 985/4885HDAC3 1827/4885HDAC1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.